Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 18, 2026 00:00 ET | Source: NovalGen Ltd.

NovalGen Appoints Dr Laurent Fischer as Chair of the Board

NovalGen appoints Dr Laurent Fischer as Chair of the Board of Directors with immediate effect.
May 14, 2026 09:45 ET | Source: Research and Markets

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Inhibitors by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of CD47 and SIRP-alpha Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
May 14, 2026 09:44 ET | Source: Research and Markets

Claudin 18.2-Targeted Immunotherapy Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Inhibitors by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Claudin 18.2-Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
May 14, 2026 09:42 ET | Source: Research and Markets

NaPi2b-Targeted Immunotherapies Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Immunotherapies by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of NaPi2b-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
May 14, 2026 09:41 ET | Source: Research and Markets

KLK2-Targeted Immunotherapies Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Immunotherapies by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of KLK2-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
May 14, 2026 09:34 ET | Source: Research and Markets

STEAP1- and STEAP2-Targeted Immunotherapies Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Immunotherapies by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of STEAP1- and STEAP2-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence...
May 14, 2026 09:33 ET | Source: Research and Markets

Tissue Factor-Targeted Immunotherapies Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Immunotherapies by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Tissue Factor-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
May 14, 2026 09:28 ET | Source: Research and Markets

DLL3-Targeted Immunotherapy Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Immunotherapies by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "DLL3-Targeted Immunotherapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
May 14, 2026 09:27 ET | Source: Research and Markets

B7-H3 (CD276) Targeted Immunotherapy Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Immunotherapies by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "B7-H3-Targeted Immunotherapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
May 14, 2026 09:26 ET | Source: Research and Markets

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Therapies by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of IGF-1R- and IGF-1 Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...